Efficacy and safety of alogliptin versus acarbose in Chinese type 2 diabetes patients with high cardiovascular risk or coronary heart disease treated with aspirin and inadequately controlled with metformin monotherapy or drug-naive: A multicentre, randomized, open-label, prospective study (ACADEMIC).

Author: GaoBin, GaoWeiguo, JiQiuhe, WanHailong, XuFengmei, ZhangXia, ZhouRong

Overview

Alogliptin was noninferior to acarbose in controlling blood sugar levels in Chinese patients with type 2 diabetes and high cardiovascular risk. Alogliptin was associated with a lower incidence of gastrointestinal side effects (8.9% vs. 33.6%) and more patients achieved target blood sugar levels without gastrointestinal side effects.

Paper Details　

Original Abstract of the Article :

AIMS: To demonstrate the noninferiority of alogliptin to acarbose, in terms of antidiabetic efficacy, in Chinese people with uncontrolled type 2 diabetes (T2D) and high cardiovascular risk. MATERIALS AND METHODS: ACADEMIC (NCT03794336) was a randomized, open-label, phase IV study conducted at 46 si...See full text at original site

Dr.Camel's Paper Summary Blog

Alogliptin vs. Acarbose: A Comparative Study in Chinese Patients with Type 2 Diabetes

Managing [type 2 diabetes (T2D)] effectively is a crucial challenge in [Endocrinology]. This study compares the efficacy and safety of [alogliptin] and [acarbose] in Chinese patients with uncontrolled T2D and high cardiovascular risk. The researchers conducted a randomized, open-label trial to evaluate the effects of these two medications on glycemic control and gastrointestinal tolerability.

Alogliptin Demonstrates Comparable Efficacy with Improved Tolerability

The study found that [alogliptin] was noninferior to [acarbose] in terms of glycemic control, achieving comparable reductions in HbA1c levels. However, [alogliptin] was associated with a significantly lower incidence of gastrointestinal adverse events. This finding suggests that [alogliptin] may be a preferable option for patients with T2D who are at risk for gastrointestinal complications, particularly those with high cardiovascular risk.

Balancing Glycemic Control with Tolerability

This study, like a desert oasis offering both shade and water, highlights the importance of finding medications that effectively manage T2D while minimizing side effects. The study's findings demonstrate that [alogliptin] can provide a suitable alternative for patients who experience gastrointestinal issues with other medications. It underscores the need for personalized treatment approaches that consider both efficacy and tolerability to optimize patient outcomes.

Dr.Camel's Conclusion

This study is like a well-stocked caravan traversing a desert of diabetes management challenges. The findings reveal that [alogliptin] offers a promising solution for those struggling with gastrointestinal side effects from other medications. It's a reminder that the search for effective and tolerable treatments is an ongoing journey, and new discoveries can emerge, offering a path to better health.